J Am Assoc Nurse Pract. 2013 Aug;25(8):395-401. doi: 10.1111/1745-7599.12030. Epub 2013 May 7.
Androgenetic alopecia (male pattern hair loss) in the United States: What treatments should primary care providers recommend?
Androgenetic alopecia (AGA), or male pattern hair loss, affects up to 96% of Caucasian men. Characterized by gradual thinning and eventual loss of hair along frontotemporal, parietal, and vertex areas of the scalp, AGA is associated with low self-esteem, depression, and dissatisfaction with body appearance.
In this systematic review of the literature, six primary research studies conducted in the United States are evaluated for their clinical application to primary care provider practice.
Topical minoxidil 2%-5% 1 mL twice daily or finasteride 1 mg daily are recommended as first line treatments, followed by the use of Food and Drug Administration-cleared HairMax LaserComb® in patients who do not respond to first line modalities.
IMPLICATIONS FOR PRACTICE:
Further research in novel and established treatments is recommended, along with an evidence-based clinical practice guideline for practitioners in the United States.
No Pingbacks for this post yet...
Hair Loss and Hair loss treatment
JAMA Dermatol. 2013 May 22:1-5. doi: 10.1001/jamadermatol.2013.3049. [Epub ahead of print]
Autoimmune, Atopic, and Mental Health Comorbid Conditions Associated With Alopecia Areata in the United States.
Huang KP, Mullangi S, Guo Y, Qureshi AA.
OBJECTIVE To evaluate the prevalence of comorbid conditions among patients with alopecia areata (AA) seen at tertiary care hospitals in Boston, Massachusetts, during an 11-year period. DESIGN Retrospective cross-sectional study. SETTING Tertiary care hospitals in Boston, including Brigham and Women's Hospital and Massachusetts General Hospital. PARTICIPANTS We identified 3568 individuals with AA seen in the Partners health care system in Boston between January 1, 2000, and January 1, 2011. We performed comprehensive searches of the Research Patient Data Repository using International Classification of Diseases, Ninth Revision code 704.01. We randomly selected 350 patients and manually reviewed their medical records to train and validate a novel artificial intelligence program. This program then used natural language processing to review free-text medical records and confirm a diagnosis of AA. To confirm the algorithm, we manually reviewed a subset of records and found 93.9% validity. MAIN OUTCOMES AND MEASURES The prevalence of comorbid conditions was assessed. RESULTS Common comorbid conditions included autoimmune diagnoses (thyroid disease in 14.6%, diabetes mellitus in 11.1%, inflammatory bowel disease in 6.3%, systemic lupus erythematosus in 4.3%, rheumatoid arthritis in 3.9%, and psoriasis and psoriatic arthritis in 2.0%), atopy (allergic rhinitis, asthma, and/or eczema in 38.2% and contact dermatitis and other eczema in 35.9%), and mental health problems (depression or anxiety in 25.5%). We also found high prevalences of hyperlipidemia (24.5%), hypertension (21.9%), and gastroesophageal reflux disease (17.3%). This profile was different from that seen in a comparison psoriasis and psoriatic arthritis group. CONCLUSIONS AND RELEVANCE We found a high prevalence of comorbid conditions among individuals with AA presenting to academic medical centers in Boston. Physicians caring for patients with AA should consider screening for comorbid conditions.
Modiefied for hair loss treatment and hair regrowth blog use
Hair Loss and Hair Loss Treatment
Hair Loss Treatment
Hair-Loss-Treatment.com enough said.
Adv Nurse Pract. 1999 Apr;7(4):39-42, 83. Hair-raising. The latest news on male-pattern baldness.
The initiating event in balding seems to be an abnormal sensitivity to the male sex hormones. In addition, a multifactorial model is emerging in which hormones affect the hair follicle in a way that causes it to be perceived as a foreign body by the immune system, which then mounts an attack. Several new classes of agents have the potential to treat hair loss. More than 40 U.S. and several hundred foreign patents have been issued for hair-loss treatment agents. As is common in dermatology, no single agent works universally against hair loss, so the treatment process is often one of trial and error.
This is a paper by Dr. Proctor